Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic

chronic hepatitis
velpatasvir
hepatitis b
sofosbuvir
  • 2 views
  • 12 Sep, 2021
  • 1 location
Re-treatment of HCV Following DAA Failure

velpatasvir [VEL]). Globally, DAA based regimens have obtained excellent rates of cure. Cure of HCV infection is defined as undetectable HCV RNA 12 weeks after stopping drugs, also referred to as sustained

ribavirin
daclatasvir
sofosbuvir
velpatasvir
ledipasvir
  • 19 views
  • 02 Mar, 2022
  • 2 locations
The Kentucky Viral Hepatitis Treatment Study (KeY Treat)

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether …

sofosbuvir/velpatasvir
antiviral agents
antiviral drugs
epclusa
viral hepatitis
  • 13 views
  • 24 Feb, 2022
  • 1 location
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (STORC)

This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy. Treatment will be initiated during the second or

  • 0 views
  • 06 May, 2022
  • 1 location
Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

of sofosbuvir/velpatasvir therapy initiated at 2 weeks postpartum. Feasibility/acceptability and adherence to sofosbuvir/velpatasvir will be assessed at 4, 8 and 12 weeks of therapy. In Phase 3

chronic hepatitis
velpatasvir
hepatitis b
sofosbuvir
  • 44 views
  • 28 Feb, 2022
  • 1 location
  • 10 views
  • 26 Mar, 2022
  • 2 locations
Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan

This trial is linked to a largescale observational study determining the efficacy of sofosbuvir/daclatasvir in people in Pakistan (involving a separate protocol). The observational study will identify a cohort of patients who have not responded to first-line antiviral therapy (sofosbuvir plus daclatasvir) and the optimal treatment for these patients is …

  • 0 views
  • 14 Mar, 2022
  • 1 location
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

This study aims to evaluate the efficacy, safety and feasibility of four weeks of sofosbuvir plus glecaprevir-pibrentasvir, followed by immediate retreatment of virological relapse with glecepravir-pibrentasvir for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).

  • 0 views
  • 27 Apr, 2022
  • 3 locations
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (SCALE-C)

A community-based "test and treat" intervention integrating point-of-care HCV RNA testing, non-invasive liver disease assessment and linkage to care will lead to a reduction in HCV prevalence among people attending Aboriginal health services.

sofosbuvir
glecaprevir/pibrentasvir
pibrentasvir
liver disease
hepatitis
  • 60 views
  • 28 Apr, 2022
  • 4 locations
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection

The investigators aim to assess the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks in hepatitis C virus (HCV)-infected patients who fail to prior NS5A

  • 0 views
  • 09 Nov, 2021
  • 15 locations